Goldman Sachs Optimistic About Regenxbio’s Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Assessing Regenxbio: Insights From 4 Financial Analysts
In the latest quarter, 4 analysts provided ratings for Regenxbio (NASDAQ:RGNX), showcasing a mix of bullish and bearish…
Evaluating Regenxbio: Insights From 9 Financial Analysts
During the last three months, 9 analysts shared their evaluations of Regenxbio (NASDAQ:RGNX), revealing diverse outlooks from bullish…
Where Regenxbio Stands With Analysts
Analysts’ ratings for Regenxbio (NASDAQ:RGNX) over the last quarter vary from bullish to bearish, as provided by 9…
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related
Gene Therapy Player REGENXBIO’s RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.
Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: ‘You Might Be Missing Out On Some Huge Gains’
Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments.
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.
Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results.
Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?
REGENXBIO's progress in Duchenne muscular dystrophy and MPS II treatment trials. Interim results for RGX-202 in Phase 1/2 trial and significant milestones achieved in Phase 1/2/3 trial with RGX-121.